ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.254,18
1,03%
S&P 500
5.473,17
-0,25%
Dow Jones
39.134,76
0,77%
Euro vs US Dollar
1,07178
0,10%
Bitcoin
64.611,17
-0,32%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Vivos Therapeutics Inc (VVOS)

  7. Vivos Therapeutics Inc (VVOS) News

VVOS

Vivos Therapeutics (VVOS)

Vivos Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VVOS
DatumZeitQuelleÜberschriftSymbolFirma
14/06/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
12/06/202413h30GlobeNewswire Inc.Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution AllianceNASDAQ:VVOSVivos Therapeutics Inc
20/05/202419h04GlobeNewswire Inc.Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote “FOR” Re-Election of Its Highly Qualified DirectorsNASDAQ:VVOSVivos Therapeutics Inc
17/05/202422h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
15/05/202420h54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
14/05/202422h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VVOSVivos Therapeutics Inc
14/05/202422h05GlobeNewswire Inc.Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational UpdateNASDAQ:VVOSVivos Therapeutics Inc
14/05/202413h30GlobeNewswire Inc.Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference CallNASDAQ:VVOSVivos Therapeutics Inc
09/04/202413h30GlobeNewswire Inc.Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementNASDAQ:VVOSVivos Therapeutics Inc
28/03/202421h05GlobeNewswire Inc.Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateNASDAQ:VVOSVivos Therapeutics Inc
28/03/202412h30GlobeNewswire Inc.Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallNASDAQ:VVOSVivos Therapeutics Inc
15/02/202414h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
15/02/202414h00GlobeNewswire Inc.Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsNASDAQ:VVOSVivos Therapeutics Inc
14/02/202423h42Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VVOSVivos Therapeutics Inc
06/02/202413h30GlobeNewswire Inc.Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesNASDAQ:VVOSVivos Therapeutics Inc
08/01/202413h30GlobeNewswire Inc.Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSANASDAQ:VVOSVivos Therapeutics Inc
11/12/202313h30GlobeNewswire Inc.Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”NASDAQ:VVOSVivos Therapeutics Inc
04/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VVOSVivos Therapeutics Inc
01/12/202322h12Edgar (US Regulatory)Form 424B1 - Prospectus [Rule 424(b)(1)]NASDAQ:VVOSVivos Therapeutics Inc
30/11/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
30/11/202322h03Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:VVOSVivos Therapeutics Inc
29/11/202313h30GlobeNewswire Inc.Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep ApneaNASDAQ:VVOSVivos Therapeutics Inc
22/11/202322h46Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:VVOSVivos Therapeutics Inc
14/11/202322h05GlobeNewswire Inc.Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational UpdateNASDAQ:VVOSVivos Therapeutics Inc
09/11/202322h30GlobeNewswire Inc.Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference CallNASDAQ:VVOSVivos Therapeutics Inc
03/11/202322h00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VVOSVivos Therapeutics Inc
02/11/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
02/11/202322h00GlobeNewswire Inc.Vivos Therapeutics Closes $4 Million Private PlacementNASDAQ:VVOSVivos Therapeutics Inc
31/10/202313h00GlobeNewswire Inc.Vivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:VVOSVivos Therapeutics Inc
27/10/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VVOSVivos Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VVOS

Kürzlich von Ihnen besucht

NASDAQ
MSFT
Microsoft
AMEX
XLE
Energy Select Sector SPDR
CCOM
US30
US 30
USOTC
ADDYY
Adidas (QX)
USOTC
RHHBY
Roche (QX)
NYSE
KO
Coca Cola
DBI
SDXP
SDAX
COIN
BTCUSD
Bitcoin
TG
ALV
Allianz
CCOM
US500
US 500
FX
EURGBP
Euro vs Sterling
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
GOOGL
Alphabet
CCOM
US100
US Tech 100
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten